Disruption of Caldesmon Gene Expression in Bladder Myocytes

膀胱肌细胞中 Caldesmon 基因表达的破坏

基本信息

  • 批准号:
    7023791
  • 负责人:
  • 金额:
    $ 35.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-03-01 至 2010-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this proposal is to develop and characterize two tools to study the physiological function for caldesmon (CaD), an actin/calmodulin-binding protein associated with smooth muscle thin filaments and thought to play a role in the maintenance of smooth muscle contractile apparatus and the regulation of contraction. These tools are 1) a knockout (KO) mouse model with disruption of the gene that encodes CaD and 2) a rabbit bladder smooth muscle cell line (BSM) which maintains the smooth muscle phenotype, including the ability to contract in response to agonists. We have been successful in making a CaD mouse KO model by homologous recombination. This CaD KO model lacks the C-terminal functional domains, important for inhibition of actin-activated ATP hydrolysis by myosin, actin-and tropomyosin-binding and tethering of myosin to actin. This model requires further characterization with respect to the effect of deletion of functional domains on the structure and function of CaD. Using myocytes dissociated from urinary bladders, muscle strips and whole bladders, we have generated preliminary data, which reveal changes in the structural and functional phenotypes in the KO mouse when compared with that of the wild-type (WT). Similarly, our preliminary studies on the BSM cell line show that the overexpression of smooth muscle specific CaD (h-CaD) in h-CaD-deficient myocytes favors the assembly of cytoplasmic filaments, including myosin filaments. The effect of deletion of CaD C-terminal functional domains on force, ATPase, and organization of cytoplasmic filaments will be studied using myocytes from CaD KO and the BSM cells after silencing the expression of CaD with siRNA or after over- or under-expression of intact or truncated CaD by transfection with CaD cDNA. Characterization of these two models (the transgenic mouse and bladder myocyte cell models) and the data from proposed studies would help to establish a role for CaD in the maintenance of the contractile apparatus and contraction. This is particularly important, since CaD is present in all urologic smooth muscles and its expression is altered in diseases associated with contractile dysfunction. The expected data would also show what effects the deletion of the CaD functional domains has on the differentiated state of the myocyte and the function of organs which depend on smooth muscle contraction. Loss of the differentiated state of the myocyte and alterations in function are correlated with decreased smooth muscle contraction in diseases such as bladder outlet obstruction, urinary incontinence, and erectile dysfunction. Furthermore, this reagent mouse and cell line would be beneficial to other investigators to study not only the role of CaD in bladder smooth muscle but also to study the signal transduction, structure and contractile function in various regions of the urogenital system.
DESCRIPTION (provided by applicant): The goal of this proposal is to develop and characterize two tools to study the physiological function for caldesmon (CaD), an actin/calmodulin-binding protein associated with smooth muscle thin filaments and thought to play a role in the maintenance of smooth muscle contractile apparatus and the regulation of contraction. These tools are 1) a knockout (KO) mouse model with disruption of the gene that encodes CaD and 2) a rabbit bladder smooth muscle cell line (BSM) which maintains the smooth muscle phenotype, including the ability to contract in response to agonists. We have been successful in making a CaD mouse KO model by homologous recombination. This CaD KO model lacks the C-terminal functional domains, important for inhibition of actin-activated ATP hydrolysis by myosin, actin-and tropomyosin-binding and tethering of myosin to actin. This model requires further characterization with respect to the effect of deletion of functional domains on the structure and function of CaD. Using myocytes dissociated from urinary bladders, muscle strips and whole bladders, we have generated preliminary data, which reveal changes in the structural and functional phenotypes in the KO mouse when compared with that of the wild-type (WT). Similarly, our preliminary studies on the BSM cell line show that the overexpression of smooth muscle specific CaD (h-CaD) in h-CaD-deficient myocytes favors the assembly of cytoplasmic filaments, including myosin filaments. The effect of deletion of CaD C-terminal functional domains on force, ATPase, and organization of cytoplasmic filaments will be studied using myocytes from CaD KO and the BSM cells after silencing the expression of CaD with siRNA or after over- or under-expression of intact or truncated CaD by transfection with CaD cDNA. Characterization of these two models (the transgenic mouse and bladder myocyte cell models) and the data from proposed studies would help to establish a role for CaD in the maintenance of the contractile apparatus and contraction. This is particularly important, since CaD is present in all urologic smooth muscles and its expression is altered in diseases associated with contractile dysfunction. The expected data would also show what effects the deletion of the CaD functional domains has on the differentiated state of the myocyte and the function of organs which depend on smooth muscle contraction. Loss of the differentiated state of the myocyte and alterations in function are correlated with decreased smooth muscle contraction in diseases such as bladder outlet obstruction, urinary incontinence, and erectile dysfunction. Furthermore, this reagent mouse and cell line would be beneficial to other investigators to study not only the role of CaD in bladder smooth muscle but also to study the signal transduction, structure and contractile function in various regions of the urogenital system.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAMUEL K. CHACKO其他文献

SAMUEL K. CHACKO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAMUEL K. CHACKO', 18)}}的其他基金

Bladder Wall Remodeling in LUTS
LUTS 中的膀胱壁重塑
  • 批准号:
    7940002
  • 财政年份:
    2009
  • 资助金额:
    $ 35.02万
  • 项目类别:
Bladder Wall Remodeling in LUTS
LUTS 中的膀胱壁重塑
  • 批准号:
    7868944
  • 财政年份:
    2009
  • 资助金额:
    $ 35.02万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7509061
  • 财政年份:
    2007
  • 资助金额:
    $ 35.02万
  • 项目类别:
Cellular and Molecular Basis of Detrucor Contractility and Bladder Dysfunction in
膀胱收缩力和膀胱功能障碍的细胞和分子基础
  • 批准号:
    7500601
  • 财政年份:
    2007
  • 资助金额:
    $ 35.02万
  • 项目类别:
Effect of Extracellular Matrix and Stretch on the Expression of Smooth Muscle Phe
细胞外基质和拉伸对平滑肌Phe表达的影响
  • 批准号:
    7500600
  • 财政年份:
    2007
  • 资助金额:
    $ 35.02万
  • 项目类别:
Disruption of Caldesmon Gene Expression in Bladder Myocytes
膀胱肌细胞中 Caldesmon 基因表达的破坏
  • 批准号:
    7173397
  • 财政年份:
    2005
  • 资助金额:
    $ 35.02万
  • 项目类别:
Disruption of Caldesmon Gene Expression in Bladder Myocytes
膀胱肌细胞中 Caldesmon 基因表达的破坏
  • 批准号:
    7564737
  • 财政年份:
    2005
  • 资助金额:
    $ 35.02万
  • 项目类别:
Disruption of Caldesmon Gene Expression in Bladder Myocytes
膀胱肌细胞中 Caldesmon 基因表达的破坏
  • 批准号:
    6861449
  • 财政年份:
    2005
  • 资助金额:
    $ 35.02万
  • 项目类别:
Disruption of Caldesmon Gene Expression in Bladder Myocytes
膀胱肌细胞中 Caldesmon 基因表达的破坏
  • 批准号:
    7346952
  • 财政年份:
    2005
  • 资助金额:
    $ 35.02万
  • 项目类别:
MYOSIN ISOFORMS & CALCIUM REGULATION OF ACTOMYOSIN ATPASE IN DETRUSOR
肌球蛋白异构体
  • 批准号:
    6346141
  • 财政年份:
    2000
  • 资助金额:
    $ 35.02万
  • 项目类别:

相似海外基金

Consequences of myosin-1G dimerization on its regulated interaction with actin
肌球蛋白-1G 二聚化对其与肌动蛋白相互作用调节的影响
  • 批准号:
    9756194
  • 财政年份:
    2018
  • 资助金额:
    $ 35.02万
  • 项目类别:
Impact of cardiomyopathy mutations on cardiac myosin structure and function
心肌病突变对心肌肌球蛋白结构和功能的影响
  • 批准号:
    9220678
  • 财政年份:
    2016
  • 资助金额:
    $ 35.02万
  • 项目类别:
Impact of cardiomyopathy mutations on cardiac myosin structure and function
心肌病突变对心肌肌球蛋白结构和功能的影响
  • 批准号:
    9028146
  • 财政年份:
    2016
  • 资助金额:
    $ 35.02万
  • 项目类别:
Phosphorylation of cMyBP-C Modulates Cardiac Arrhythmias
cMyBP-C 磷酸化调节心律失常
  • 批准号:
    8763886
  • 财政年份:
    2013
  • 资助金额:
    $ 35.02万
  • 项目类别:
Phosphorylation of cMyBP-C Modulates Cardiac Arrhythmias
cMyBP-C 磷酸化调节心律失常
  • 批准号:
    8596465
  • 财政年份:
    2013
  • 资助金额:
    $ 35.02万
  • 项目类别:
cMyBPC and Regulation of Myocardial Contraction
cMyBPC 和心肌收缩的调节
  • 批准号:
    7839733
  • 财政年份:
    2009
  • 资助金额:
    $ 35.02万
  • 项目类别:
Regulation of Contractility During Ischemia-Reperfusion
缺血再灌注过程中收缩力的调节
  • 批准号:
    7837479
  • 财政年份:
    2009
  • 资助金额:
    $ 35.02万
  • 项目类别:
Energy Transduction in Myosin
肌球蛋白的能量转导
  • 批准号:
    7921781
  • 财政年份:
    2008
  • 资助金额:
    $ 35.02万
  • 项目类别:
Determinants of Cardiac Thin Filament Regulation
心脏细丝调节的决定因素
  • 批准号:
    7685309
  • 财政年份:
    2008
  • 资助金额:
    $ 35.02万
  • 项目类别:
Troponin and myosin in regulation of muscle contraction and heart disease
肌钙蛋白和肌球蛋白调节肌肉收缩和心脏病
  • 批准号:
    8197235
  • 财政年份:
    2008
  • 资助金额:
    $ 35.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了